BioCorRx director Kate Beebe DeVarney resigns
BioCorRx Inc. announces the resignation of director Kate Beebe DeVarney, Ph.D., effective August 31, 2026, stating there was no disagreement with the company.
Rhea-AI Filing Summary
BioCorRx Inc. (BICX) reports that Kate Beebe DeVarney, Ph.D. resigned from its board of directors, effective August 31, 2026. The company states that her resignation did not arise from any disagreement with BioCorRx Inc. or its subsidiary, BioCorRx Pharmaceuticals.
Positive
- None.
Negative
- None.
Filing Explained
Effective August 31, 2026, Kate Beebe DeVarney no longer serves on BioCorRx’s board, changing the company’s board composition.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Resignation effective date: August 31, 2026
Report signature date: September 4, 2026
2 metrics
Resignation effective date
August 31, 2026
Effective date of Kate Beebe DeVarney, Ph.D.’s resignation from the board of directors
Report signature date
September 4, 2026
Date the CEO signed the current report on behalf of BioCorRx Inc.
Key Terms
Emerging growth company, board of directors, subsidiary, Section 12(b)
4 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
board of directors regulatory
"her position as a member of the board of directors"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
subsidiary financial
"nor BioCorRx Pharmaceuticals, a subsidiary of the Company"
A subsidiary is a company that is controlled or owned by a larger company, known as the parent company. Think of it like a branch or division of a bigger organization; it operates separately but is ultimately guided by the parent. For investors, understanding subsidiaries helps clarify how a larger company is structured and where its resources and risks are concentrated.
Section 12(b) regulatory
"Securities registered pursuant to Section 12(b) of the Act"
Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.
FAQ
What board change did BioCorRx Inc. (BICX) disclose in this 8-K?
BioCorRx Inc. disclosed that Kate Beebe DeVarney, Ph.D. resigned as a member of its board of directors, effective August 31, 2026. The company noted that her resignation was not due to any disagreement with BioCorRx Inc. or its subsidiary.
When was the director resignation at BioCorRx Inc. (BICX) effective?
The resignation of director Kate Beebe DeVarney, Ph.D. from the board of BioCorRx Inc. was effective on August 31, 2026, the same date she submitted her resignation to the company.
Which subsidiary of BioCorRx Inc. is mentioned in connection with the resignation?
The filing mentions BioCorRx Pharmaceuticals, a subsidiary of BioCorRx Inc., and clarifies that Kate Beebe DeVarney’s resignation did not result from any disagreement with this subsidiary or with the parent company.
Who signed the BioCorRx Inc. (BICX) 8-K reporting the director resignation?
The 8-K was signed on behalf of BioCorRx Inc. by Lourdes Felix, the company’s Chief Executive Officer, dated September 4, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
